A Study of TAS-120 in Patients With Metastatic Breast Cancer

Official Title

A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications

Summary:

The purpose of the trial is to evaluate a patient's response to a Fibroblast Growth Factor Receptor (FGFR) inhibitor, futibatinib (TAS-120), used either alone or in combination with the hormonal therapy, fulvestrant. This study will be conducted in patients with metastatic breast cancer who have specific Fibroblast Growth Factor Receptor gene abnormalities and who have previously received conventional therapies to treat their breast cancer, or who are not able to tolerate certain cancer therapies. This study will also evaluate the safety of taking futibatinib, or futibatinib and fulvestrant, by learning about the potential side effects.

Trial Description

Primary Outcome:

  • Objective Response Rate (ORR) - Cohorts 1, 2
  • Clinical Benefit Rate (CBR) - Cohort 3
  • 6-month Progression-free Survival (PFS) rate - Cohort 4
Secondary Outcome:
  • Complete Response (CR) - Cohort 3
  • Overall Response Rate (ORR) - Cohort 4
  • Clinical Benefit Rate (CBR) - Cohort 1,2, and 4
  • 6-month Progression-free Survival (PFS) rate - Cohorts 1-3
  • Progression-free Survival (PFS)
  • Duration of Response (DOR)
  • Overall Survival (OS)
  • Number of Adverse Events (AEs) Related to TAS-120 as a monotherapy and in combination with Fulvestrant
  • Number of Adverse Events (AEs) Related to Futibatinib as a monotherapy and in combination with Fulvestrant

This is a Phase 2, open-label, non-randomized, multicenter study designed to evaluate the efficacy and safety of futibatinib (TAS-120) and futibatinib + fulvestrant in up to 168 adult patients with locally advanced/metastatic breast cancer harboring FGFR gene amplifications. Patients will be enrolled to 1 of 4 treatment cohorts based on diagnosis and FGFR gene amplification status, and will receive either single agent futibatinib in Cohorts 1-3 or futibatinib plus fulvestrant in Cohort 4, as follows:

  • Cohort 1 - HR+ HER2- Measurable Disease w/ FGFR2 Amplification
  • Cohort 2 - TNBC Measurable Disease w/ FGFR2 Amplification
  • Cohort 3 - HR+ HER2- or TNBC Non-Measurable Disease w/ FGFR2 Amplification
  • Cohort 4 - HR+ HER2- Measurable Disease w/ FGFR1 Amplification

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society